Tvardi Therapeutics’ (TVRD) Buy Rating Reiterated at HC Wainwright

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Friday, Benzinga reports. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at ($1.51) EPS and FY2028 earnings at ($1.56) EPS.

A number of other analysts have also issued reports on the stock. BTIG Research dropped their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, October 2nd. Chardan Capital assumed coverage on shares of Tvardi Therapeutics in a report on Tuesday, October 20th. They set a “buy” rating for the company. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 1st. Finally, Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $9.40.

Get Our Latest Stock Analysis on TVRD

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $0.95 on Friday. The company has a market cap of $12.64 million, a P/E ratio of -0.35 and a beta of 0.37. Tvardi Therapeutics has a one year low of $0.77 and a one year high of $5.69. The business’s 50-day simple moving average is $1.16 and its 200 day simple moving average is $2.54.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.03. Analysts predict that Tvardi Therapeutics will post -2.22 earnings per share for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $181,000. Susquehanna International Group LLP bought a new position in Tvardi Therapeutics during the second quarter worth $63,000. Finally, GSA Capital Partners LLP acquired a new position in Tvardi Therapeutics in the second quarter worth $34,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

(Get Free Report)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.

See Also

Analyst Recommendations for Tvardi Therapeutics (NASDAQ:TVRD)

Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.